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Abstract
Background: Little is known about the prognostic impact of cirrhosis on long-term survival of patients with
combined hepatocellular-cholangiocarcinoma (cHCC-CC) after hepatic resection. The aim of this study was to
elucidate the long-term outcome of hepatectomy in cHCC-CC patients with cirrhosis.
Methods: A total of 144 patients who underwent curative hepatectomy for cHCC-CC were divided into two
groups: cirrhotic group (n = 91) and noncirrhotic group (n = 53). Long-term postoperative outcomes were
compared between the two groups.
Results: Patients with cirrhosis had worse preoperative liver function, higher frequency of HBV infection, and
smaller tumor size in comparison to those without cirrhosis. The 5-year overall survival rate in cirrhotic group was
significantly lower than that in non-cirrhotic group (34.5% versus 54.1%, P = 0.032). The cancer recurrence-related
death rate was similar between the two groups (46.2% versus 39.6%, P = 0.446), while the hepatic insufficiency-related
death rate was higher in cirrhotic group (12.1% versus 1.9%, P = 0.033). Multivariate analysis indicated that cirrhosis
was an independent prognostic factor of poor overall survival (hazard ratio 2.072, 95% confidence interval
1.041–4.123; P = 0.038).
Conclusions: The presence of cirrhosis is significantly associated with poor prognosis in cHCC-CC patietns after
surgical resection, possibly due to decreased liver function.
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Background
Combined hepatocellular-cholangiocarcinoma (cHCC-CC)
is a very rare entity that includes elements of both hepato-
cellular carcinoma (HCC) and cholangiocarcinoma (CC)
and represents 0.4–14.2% of primary liver malignancies [1].
Hepatic resection affords the best chance of long-term
survival with a reported 5-year overall survival (OS) rate of
23.1–54.1%. Vascular invasion, lymph node metastasis,
satellite nodules, and tumor size were reported as prognos-
tic factors [2–5].
Patients with cHCC-CC, especially in Asian countries,
are frequently accompanied by liver cirrhosis, with a
prevalence of 27.7–84.6% [6]. However, little is known
about the prognostic significance of cirrhosis in cHCC-CC
patients after surgery. In this study, we compared the
long-term outcomes of hepatic resection in cHCC-CC
patients with and without cirrhosis.
Methods
Patients
From February 2000 to December 2011, 151 patients with
cHCC-CC who underwent curative resection at our insti-
tutes. Curative resection was defined as complete excision
of the tumor with clear microscopic margin conformed by
histopathological examination. Allen and Lisa [7]
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categorized cHCC-CC into three types; type A: HCC
and CC exist separately (double cancer); type B: HCC
and CC exist contiguously but independentlyonly; and
type C: HCC and CC components show contiguity with
intermingling. Histologically, only type C tumors that
displayed the characteristics of a genuine mixture of
both HCC and CC elements were regarded as true
combined tumors [5]. Seven patients with Allen type A
and B tumors were therefore excluded from the study.
Finally, 144 patients were subjected to this study. Of
them, 91 (63.2%) patients had cirrhosis as confirmed by
histology and the remaining 53 (36.8%) patients did not
have cirrhosis. Patient demographics, operative data,
tumor characteristics, and follow-up findings were
reviewed retrospectively. Postoperative morbidity and
mortality were analyzed 90 days after operation. Liver dys-
function was defined as total bilirubin level >10 mg/dL
unrelated to biliary obstruction or leak and/or the
international normalized ratio >2 for more than 2 days
after resection and/or clinically significant ascites/hepatic
encephalopathy [8].
All patients were followed postoperatively by serum
tumor marker (alpha-fetoprotein [AFP] and carbohy-
drate antigen 19–9 [CA 19–9]) analysis and ultrasound
or computed tomography at least every 3 months in the
first year after hepatectomy, and then at gradually in-
creasing intervals. Intrahepatic recurrence was identified
by new lesions on imaging with typical appearances of
cHCC-CC with or without a rising serum AFP or CA
19–9 level. Determination of treatment strategy for re-
current tumors depended on the number and site of the
tumors, any concurrent extrahepatic recurrence, liver
function, and the general status of the patient. Re-
hepatectomy and percutaneous radiofrequency ablation
(PRFA) were considered as first-choice treatments. Re-
hepatectomy was performed for Child A patients with
solitary or multiple tumors limited in the semi-liver with
sufficient liver remnant volume. PRFA was given to
Child A and selected Child B patients with solitary
tumor ≦3 cm located deeply in the liver parenchyma or
multiple tumors (up to 3 lesions all ≦ 3 cm) in different
lobes without vascular invasion or gross ascites. Transar-
terial chemoembolization (TACE) was considered when
the above two treatments were not possible, as in pa-
tients with advanced multinodular recurrent tumors,
poor liver function, and insufficient liver remnant vol-
ume. Systemic chemotherapy or conservative treatment
was considered for patients with extensive systemic
recurrence and/or very poor liver function or general
condition.
Statistical analysis
Categorical and continuous data were compared by the
χ2 test and the Student t test, respectively. Patient OS
and disease-free survival (DFS) rates were estimated
using the Kaplan-Meier method, and differences be-
tween groups were compared by log-rank test. Multi-
variate analysis was performed by the Cox proportional
hazard regression model. All statistical analyses were
performed using SPSS for Windows (version 11.0; SPSS
Institute, Chicago, IL, USA). P < 0.05 was considered sta-
tistically significant.
Results
Patient characteristics and outcomes
The clinicopathologic data of noncirrhotic and cirrhotic
patients are summarized in Table 1. Cirrhotic patients had
higher prevalence of men, alcohol abuse, and positive
hepatitis B surface antigen (HBsAg), higher serum alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) levels, higher prevalence of abnormal serum AFP
level, and smaller tumors than non-cirrhotic patients.
Regarding operative procedures and preoperative out-
comes, less major resection (≥3 segments) was applied
in cirrhotic patients. Postoperative morbidity was similar
in the two groups except for the higher incidence of liver
dysfunction in cirrhotic group. One patient in cirrhotic
group died of hepatorenal failure resulting in a mortality
rate of 1.1%, showing no statistically significant differ-
ence with 0% in non-cirrhotic group (Table 2).
The median postoperative follow-up period was 35
(range 3–127) months. The 5-year DFS rate was similar
between cirrhotic and non-cirrhotic patients (29.6%
versus 38.7%, P = 0.079). However, the 5-year OS rate
and the median OS time in cirrhotic group was signifi-
cantly lower than that in non-cirrhotic group, with
values of 34.5% and 31 months, versus 54.1% and
63 months, respectively (P = 0.032) (Fig. 1).
By the time of analysis, recurrences developed in 68 cir-
rhotic and 35 non-cirrhotic patients with a similar fre-
quency (75.5% versus 66.1%, P = 0.567). Also, there was no
difference in the median time to recurrence and the pat-
tern of recurrence between the two groups. Regarding the
initial treatment for recurrences, aggressive approaches in-
cluding re-hepatectomy and local ablation were applied
less frequently in cirrhotic patients as compared with non-
cirrhotic patients (36.8% versus 60.0%, P = 0.025) (Table 3).
Investigation on the cause of death showed that 56 cir-
rhotic patients and 23 non-cirrhotic patients died during
the follow-up period in this study (P = 0.029). Cancer
recurrence-related death was similar between cirrhotic and
non-cirrhotic group (46.2% versus 39.6%, P = 0.446), while
hepatic insufficiency-related death was more frequently
observed in cirrhotic group (12.1% versus 1.9%, P = 0.033).
Prognostic factors for overall survival
Univariate analysis showed that factors affecting OS were
maximum tumor size > 5 cm, intraoperative transfusion,
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cirrhosis, bile duct invasion, lymph node involvement, and
vascular invasion. Multivariate analysis showed that cir-
rhosis was an independent prognostic factor for poor OS
(hazard ratio 2.072, 95% confidence interval 1.041–4.123;
P = 0.038) (Table 4).
Discussion
The reported prevalence of cirrhosis in cHCC-CC pa-
tients ranges widely from 27.7% to 84.6% worldwide
based on operative findings [6]. This figure is 63.2% in
our cohort. The sex ratio of cHCC-CC shows a promin-
ent male predominance, which is compatible with the
findings of several previous reports [2–5]. It has been re-
ported that this male predominance correlated with high
activities of androgen axis, an oncogenic pathway in-
volved in hepatocarcinogenesis [9]. However, further
analysis of the precise mechanisms for male susceptibil-
ity to cHCC-CC is needed.
cHCC-CC is reportedly similar to HCC in terms of
clinicopathologic characteristics including mean age,
male/female ratio, hepatitis viral positivity, serum AFP
level, and the presence of cirrhosis [1]. Some researchers
from Asian institutions therefore speculated that cHCC-
CC represents a variant of ordinary HCC that exhibits
cholangiocellular metaplasia, rather than a true intermedi-
ate disease entity between HCC and CC [3]. As is the case
with HCC, we find that hepatitis B virus (HBV) is a main
etiologic factor in the development of cHCC-CC in a cir-
rhotic liver. Accordingly, ALT and ALT values as indica-
tors of activity or severity of the hepatitis state were both
higher in cirrhotic patients than those in non-cirrhotic pa-
tients. A comparison of the pathologic findings in resected
specimens showed the tumor size was generally smaller in






Sex (male/female), n 89/2 46/7 0.274
Age (years; mean ± SD) 53.2 ± 9.2 52.1 ± 8.1 0.463
Overweight (BMI 25.0-29.99 kg/m2), n (%) 15 (16.5) 10 (18.9) 0.716
Obesity (BMI ≥ 30 kg/m2), n (%) 3 (3.3) 2 (3.8) 0.880
Hypertension, n (%) 12 (13.2) 6 (11.3) 0.744
Diabetes mellitus, n (%) 10 (11.0) 4 (7.5) 0.501
Hepatitis B surface antigen, n (%) 79 (63.8) 22 (37.2) <0.001
Alcohol use, n (%) 24 (26.4) 5 (9.4) 0.015
Total bilirubin (μmol/L; mean ± SD) 17.8 ± 8.8 15.4 ± 4.1 0.090
Albumin (g/L; mean ± SD) 40.5 ± 5.3 41.2 ± 4.6 0.417
Aspartate aminotransferase (IU/L; mean ± SD) 51.2 ± 35.3 39.6 ± 22.3 0.021
Alanine aminotransferase (IU/L; mean ± SD) 54.5 ± 50.6 41.8 ± 36.7 0.043
Child-Pugh (A/B), n 85/6 53/0 0.056
Tumor diameter (cm; mean ± SD) 4.9 ± 2.5 6.7 ± 2.8 <0.001
Tumor number (St/Mt), n 82/9 46/7 0.541
Encapsulation, n (%) 34 (37.4) 15 (28.3) 0.268
Vascular invasion, n (%) 41 (45.1) 27 (50.9) 0.495
Bile duct invasion, n (%) 17 (18.7) 11(20.8) 0.762
Lymph node involvement, n (%) 12 (13.2) 8 (15.1) 0.750
Alpha-fetoprotein ≥ 20 ng/mL, n (%) 56 (61.5) 22 (41.5) 0.020
Carbohydrate antigen 19–9 ≥ 37 U/mL, n (%) 31 (34.1) 21 (39.6) 0.503
Carcinoembryogenic antigen ≥ 5 ng/mL, n (%) 7 (7.7) 3 (5.7) 0.644
BMI body mass index; St single tumor; Mt multiple tumors
Table 2 Comparison of operative procedures and
preoperative outcomes
Variables Cirrhosis
n = 91 (%)
Non- cirrhosis
n = 53 (%)
P-value
Extent of resection 0.006
Major resection 21 (23.1) 24 (45.3)
Minor resection 70 (76.9) 29 (54.7)
Liver disfuction 31 (34.1) 7 (13.2) 0.006
Complications other
than liver disfuction
34 (37.4) 18 (34.0) 0.682
Mortality 1 (1.1) 0 (0) 0.444
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cirrhotic group. One possible explanation for this phe-
nomenon is that cirrhotic patients generally have active
liver disease and may have image-based liver screening,
which enabled detection of small tumors. However, it
should be acknowledged that there may be a selection bias
for hepatic resection. Many cirrhotic patients were unable
to undergo hepatectomy because of poor liver function re-
serve, and most patients with large tumors may be treated
by a nonsurgical modality such as hepatic artery em-
bolization or conservative treatment.
As expected, cirrhotic patients had a significantly
higher incidence of liver dysfunction after surgical resec-
tion. As cirrhotic patients have relatively small tumours
and limited hepatic functional reserve, they usually
undergo minor hepatectomy.
The negative impact of cirrhosis on long-term survival
has been reported in postoperative HCC patients [10, 11],
but its impact on long-term survival of cHCC-CC patients
undergoing hepatectomy remains unclear. The present
study is the first to present data to indicate that the cirrho-
sis is an independent predictor for postoperative OS of
cHCC-CC patients. The 5-year OS rate was 34.5% in cir-
rhotic patients versus 54.1% in non-cirrhotic counterparts.
Fig. 1 Comparison of patient overall survival rates between the cirrhotic and non-cirrhotic groups






Median time to recurrence, months 13 14 0.693
Recurrence type, n (%)
Intrahepatic recurrence 42 (61.8) 24 (68.6) 0.495
Extrahepatic recurrence 19 (27.9) 8 (22.8) 0.578
Both 7 (10.3) 3 (8.6) 0.780
Treatment of recurrence, n (%)
Aggressive approach 25 (36.8) 21 (60.0) 0.025
Rehepatectomy 3 (4.3) 5 (14.3) 0.076
Local ablation 22 (32.4) 16 (45.7) 0.183
Transarterial chemoembolization 26 (38.2) 9 (25.7) 0.204
Systemic chemotherapy 5 (7.4) 2 (5.7) 0.754
Conservative treatment 12 (17.6) 3 (8.6) 0.216
Table 4 Multivariate analysis of risk factors for poor overall survival
Variables HR 95% CI P-value
Maximum tumor size > 5 cm 2.115 0.901–4.960 0.085
Intraoperative transfusion 1.704 1.062–2.732 0.027
Cirrhosis 2.072 1.041–4.123 0.038
Bile duct invasion 1.662 0.614–4.511 0.317
Lymph node involvement 1.943 0.829–4.490 0.126
Vascular invasion 2.583 1.380–4.834 0.002
HR hazard ratio; CI confidence interval
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This difference is likely attributable to more hepatic de-
compensation caused by ongoing cirrhosis itself in cir-
rhotic patients. As demonstrated in our study, hepatic
insufficiency-related death accounted for 11 (12.1%)
deaths in cirrhotic patients and only one (1.9%) death in
non-cirrhotic patients. Difference in treatment strategies
for recurrent disease may also account for differences in
outcomes. Cirrhotic patients usually have impaired
hepatic function after the initial hepatic resection, which
limits the application of aggressive management for
recurrence, which is often the leading cause for an
unfavorable outcome.
Several studies have documented an association be-
tween cirrhosis and recurrence of HCC, which is likely
attributable to multicentric de novo carcinogenesis in
the remnant liver [10, 12]. However, our study failed to
find such an association in cHCC-CC patients. One of
the explanations for this discrepancy is that cHCC-CC
with CC components exhibits a more aggressive behav-
ior and has high probability of intrahepatic metastasis,
which would overshadow the effect of cirrhotic liver
related-carcinogenesis.
Theoretically, liver transplantation (LT) offers the po-
tential benefit of resecting the entire tumor-bearing liver
and eliminating cirrhosis simultaneously, and therefore
it is generally believed to be an ideal approach for the
treatment of cHCC-CC in cirrhotic patients. In the three
cHCC-CC patients receiving LT reported by Chan et al.
[13], one patient died from distant metastasis 16.5 months
after operation while the other two patients survived 25
and 35 months after operation, respectively. Wu et al. [14]
reported a 5-year OS rate of 39% in a case series of 21 pa-
tients with cHCC-CC treated with LT. Panjala et al. [15]
reported a 5-year OS rate of 16% in their 12 cHCC-CC
patients receiving LT. Employing the Surveillance,
Epidemiology, and End Results database (1988–2009),
Garancini et al. [16] reported a 5-year OS rate of 41.1% in
16 cHCC-CC patients receiving LT. Currently, it is diffi-
cult to assess the effectiveness of LT in the management
of cHCC-CC because of insufficient data and limited evi-
dence available.
Conclusion
This study showed that cHCC-CC patients with cirrhosis
had a poorer long-term prognosis after surgical resection
as compared with those without cirrhosis, possibly due
to the decreased liver function.
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